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ABSTRACT 
The goal of this project was to study the effect of the presence or absence of the cofactor 
NADPH on the binding and release of ligand methotrexate (MTX) to/from Bacillus 
stearothermophilus (Bs) dihydrofolate reductase (DHFR). A previously developed, 
fluorescently-labeled Bs DHFR (C73A/S131CMDCC DHFR) was used to investigate the 
kinetics and protein conformational motions associated with the binding of NADPH and 
the binding of methotrexate to the holoenzyme.  This Bs DHFR contains a distal cysteine 
where the fluorophore, N-[2-(1-maleimidyl)ethyl]-7-(diethylamino)coumarin-3-
carboxamide (MDCC) can be covalently attached. This probe is sensitive to the local 
molecular environment, reporting on changes in the protein conformation associated with 
ligand binding. Intrinsic tryptophan fluorescence of the unlabeled Bs DHFR construct 
(C73A/S131C DHFR) was also used to detect changes in conformational motion upon 
ligand and cofactor association and dissociation. 
Previous stopped-flow data indicates the presence of two native state Bs DHFR 
conformers that bind to ligand at different rates. Similarly, two conformations of 
Escherichia coli DHFR in unbound state were reported. Intrinsic tryptophan fluorescence 
of C73A/S131C Bs DHFR and probe fluorescence of C73A/S131CMDCC Bs DHFR 
both report on ligand binding. The labeled and unlabeled DHFRs report on the two 
different conformers, respectively.  This study shows that NADPH binding significantly 
slows down the dissociation rate (approx. 1000-fold) of methotrexate from Bs DHFR 
from 0.015 ±0.007965 s-1 to 0.000021 ±0.00000271 s-1. This demonstrates the importance 
of NAHPH in the analysis and study of DHFR. 
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Introduction: 
Dihydrofolate reductase (DHFR) is an essential enzyme found in nearly all life 
forms. DHFR catalyzes the formation of tetrahydrofolate from dihydrofolate using the 
cofactor NADPH as the reducing agent. Tetrahydrofolate is required in the synthesis of 
purines, thymidylate and several amino acids and reducing its activity prevents cells from 
growing or multiplying. This makes DHFR an important pharmaceutical target for 
development of antibiotics and pharmaceuticals targeting cancer [ 41, 42 ]. 
Pharmaceuticals that inhibit DHFR’s function are known as antifolates [ 19 ]. Studying 
how these drugs interact with DHFR is important for further research into protein 
dynamics and the design of new pharmaceuticals.  
DHFR has become one of the main model systems for studying protein 
conformational motions [ 10 ]. Enzymes are thought to exist in a variety of conformations 
that are in equilibrium with each other. For many enzymes, one conformer is the stable 
state; for others, more than one stable conformer exists in equilibrium [ 13, 27 ]. An 
enzyme that exists in multiple stable conformers has the possibility of more elaborate 
regulation. Studies on how one conformer as opposed to the other binds ligands leads to a 
better understanding of potential regulation [ 1, 8, 9, 24 ]. 
 
 
Figure 1: A visualization of how enzyme conformers exist in many conformations with a 
prominent few conformations that are most stable. 
 
80% 0.2% 0.25% 19.5% 0.05% 
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Figure 2: The reaction of Dihydrofolate to Tetrahydrofolate by Dihydrofolate Reductase 
using NADPH as a cofactor. 
 
DHFR 
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 Previous published work on DHFR has demonstrated at least two stable 
conformations that bind ligands at different rates [ 30 ].  A confounding factor of this 
system is the cofactor NADPH. Most research has focused on the apoenzyme (enzyme 
without cofactor bound), presumably to avoid the complexity of the bound cofactor. As a 
result, less is known about the binding of methotrexate (MTX) to the holoenzyme 
(enzyme with cofactor bound). However, the holoenzyme needs to be studied because it 
is the biologically relevant species. Understanding the interactions between DHFR, 
NADPH, and methotrexate will increase the understanding of structure function 
relationships in DHFR. Thus, the goal is to determine the extent to which NADPH 
impacts the binding of DHFR to methotrexate and the associated conformational 
dynamics. There are three specific goals:  
• Find rates of binding and dissociation and associated conformational 
changes of methotrexate binding to Bs DHFR. 
• Determine the rates of binding and dissociation of NADPH to/from Bs 
DHFR and rates of associated conformational changes. 
• Determine the rate of methotrexate binding to the Bs DHFR holoenzyme 
(with NADPH bound), rate of release of methotrexate from holoenzyme, 
and rates of associated conformational changes. 
Stopped-flow fluorescence spectroscopy was used to determine rates of binding, 
dissociation and associated conformational changes. This method measures changes in 
fluorescence intensity over time after two fluid flows are mixed together. The 
measurement begins as the flows are stopped.  The dead time of the instrument is 
approximately one to two milliseconds. In this project, I measured changes in the 
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intensity of the intrinsic tryptophan fluorescence for the unlabeled enzyme.  I measured 
changes in the fluorescence intensity of the covalently bound fluorophore MDCC for the 
labeled enzyme.  In both measurements, the intensity of the fluorophore signal will 
change when the conformation of the Bs DHFR changes. This is because the environment 
of the fluorophore changes when the protein undergoes a conformational change. 
Integrating these two fluorescence signals allowed me to differentiate between 
binding events associated with each conformer. Each of the two conformers may have 
different biding mechanisms to methotrexate. For example, one conformer may bind 
faster than the other or release methotrexate more rapidly. There may also be 
conformational changes that are associated with the methotrexate binding event or ones 
that follow the binding event for one or both conformers. At low methotrexate 
concentrations, concentration dependent binding steps can be seen the best. At higher 
methotrexate concentrations, the concentration dependent binding steps are so fast they 
are over in the dead time of the instrument, allowing the slower concentration 
independent conformational changes to be measured clearly. With these tools, we 
determined the rates of binding events and conformational changes for the binding of 
NADPH and methotrexate to both the apoenzyme, the enzyme without its cofactor 
NADPH, and the holoenzyme, the enzyme with the cofactor NADPH bound. 
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Figure 3: A graphical representation of the structure of Bs DHFR (PDB ID: 1ZDR) [ 1 ]. 
These models show the front (top) where the MTX binding site is located and the back 
(bottom) where the MDCC fluorescent probe gets attached. Residue 131, the site of 
labeling, is shown as a magenta sphere. 
 
Material and methods  
Protein expression and purification  
An E. coli BL21 cell line transformed with C73A S131C Bs DHFR with the was 
obtained from a previous study done by Maryam Alapa [ 1 ]. The unlabeled Bs DHFR 
construct (C73A/S131C Bs DHFR) was grown and expressed in LB broth containing 100 
μg/mL ampicillin at 37 °C. OD600 was allowed to reach 0.6; expression was then induced 
using 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and the cells expressed 
overnight at 30 °C. Cells were washed in 0.9% NaCl and pelleted.  
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Figure 4: Process figure for the growth and purification of C73A S131C Bs DHFR. 
 
The cells were suspended in 40 mM N-2-hydroxyethylpiperazine-N’-2-ethanelsulfonic 
acid (HEPES) buffer at pH 6.8, then lysed by sonication at 10% duty with an output of 5 
pulsed for 4 minutes. The supernatant was loaded onto an SP-sepharose C-25 column and 
eluted with 0.2 M NaCl in 40 mM HEPES (pH 6.8). The Bs DHFR fractions were 
collected, exchanged into 40 mM HEPES (pH 6.8), concentrated, and stored at -80 °C 
with a typical yield of 2.5 mg of protein for 1 L of Expressed protein broth. The purity 
was verified by SDS-PAGE electrophoresis.  
 
LB Broth + 100 µg Ampicillin + Cells 
37˚C 
At OD600=0.6 Induced 
with IPTG 
30˚C 
Use centrifuge to 
pellet cells 
Dissolve + sonicate cell pellet 
Centrifuge 
Run supernatant through anion 
exchange column 
Use centrifugal filter tubes 
to wash and concentrate  
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                Ladder    A            B            C      D         E        Ladder      F 
 
Figure 5: This is a typical gel for the purification of C73A/S131C Bs DHFR using a SP-
sepharose C-25 column. The molecular weight of Bs DHFR is 18.6 kDa A) lysate, B) 
flow column 1, C) flow column 2, D) eluted DHFR 1, E) eluted DHFR 2, F) concentrated 
DHFR (approximately 0.002 mg) at very high purity.  
 
Preparation of C73A/S131CMDCC Bs DHFR  
Covalent attachment of the MDCC fluorophore to cysteine on the Bs DHFR 
complex at position 131 was initiated by adding a 3-fold molar excess of 0.22 mM stock 
solution of MDCC fluorophore (ThermoFisher Scientific, Catalog number:  D10253,     
7-Diethylamino-3-((((2-Maleimidyl)ethyl)amino)carbonyl)coumarin, MW 383.4 g/mol), 
dissolved in dimethyl sulfoxide, to purified C73A/S131C Bs DHFR in pH 7.2 HEPES 
buffer. The final concentrations were 139.1 μM of MDCC and 41.5 μM of Bs DHFR with 
kDa 
 
 
116 
 
 
66.2 
 
45 
 
35 
25/18.4 
14.4 
8 
 
a final volume of 1.65 mL. The mixture was covered with aluminum foil to protect the 
sample from light and incubated at room temperature for 2 h. The sample was dialyzed 
twice, once for 4 h at 4 °C and once overnight at 4 °C in HEPES pH 6.8 to remove excess 
dye and to exchange buffer. The extinction coefficient of DHFR (25,565 M−1cm−1 at 280 
nm) and of MDCC (10,000 M−1cm−1 at 280 nm and 50,000 M−1cm−1 at 419 nm) were 
used to calculate labeling efficiency. Labeling efficiency was found to be ~99.4 % from 
absorbance measurements at 280 and 419 nm using a Thermo Scientific NanoDrop 2000c 
UV-Vis spectrophotometer.  
 
Figure 6: This shows the equation and constants used in the calculation of enzyme 
concentration, amount of MDCC needed for the labeling, and the labeling efficiency. 
Labeling efficiency is calculated by comparing the concentration calculation of MDCC at 
419 nm to the concentration calculation of DHFR at 280nm (subtracting out the A280 of 
MDCC from the total). Sample calculation Fig. 19 in Appendix. 
 
Unlabeled apoenzyme Bs DHFR mixed with methotrexate 
Methotrexate (2–200 µM) was mixed with 2 µM of C73A/S131C Bs DHFR in 50 
mM 2-(N-morpholino) ethanesulfonic acid, 25 mM tris(hydroxymethyl)-aminomethane, 
25 mM ethanolamine, and 100 mM NaCl (MTEN buffer) at pH 7 in an Applied 
Photophysics SX20 stopped-flow apparatus. The changes in fluorescence emission 
Absorption = Extinction coefficient * Concentration * Distance 
   (M -1 cm -1)      (M)         (cm) 
A280 DHFR     25565              0.1 
A280 MDCC   10000              0.1 
A419 MDCC   50000              0.1 
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intensity for C73A/S131C Bs DHFR (excitation at 290 nm, emission with a 320 nm 
cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25 – 
500 s. Five individual traces were used to obtain an average trace for each condition. 
Control data for responses were obtained by taking fluorescence readings of each 
component when separately when combined in the stopped-flow apparatus with buffer. 
For example, to determine the contribution of DHFR to the fluorescence of the 
DHFR/MTX experiment, DHFR was mixed in the stopped-flow cell with buffer and the 
fluorescence measured. 
To measure the dissociation rate of the DHFR-MTX complex, 2 μM enzyme was 
incubated with 10 μM methotrexate in MTEN buffer at pH 7. The enzyme-methotrexate 
solution was then mixed in a stopped-flow apparatus with 300 μM or 700 μM 
trimethoprim (TMP) which displaces methotrexate in the active site. The dissociation 
event was monitored by following the fluorescence emission changes at 320 nm for 500s. 
To further explore the dissociation rate of the DHFR-MTX complex a 
concentration of 1 μM enzyme, 5 μM methotrexate, and 700 μM trimethoprim (TMP) in 
MTEN buffer at pH 7 was mixed (TMP mixed in immediately prior to fluorescence 
readings) and placed in a Flouromax SX20 spectrophotometer. The dissociation event 
was monitored by following the fluorescence emission changes at 320 nm for 600s and 
172800s (48h). 
 
Labeled apoenzyme Bs DHFR mixed with methotrexate 
Methotrexate (2– 200 µM) was mixed with 2 µM of C73A/S131CMDCC Bs DHFR 
in MTEN buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence 
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emission intensity for C73A/S131CMDCC (excitation at 419 nm, emission with a 450 nm 
cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25-
500s. Five individual traces were used to obtain an average trace for each condition. 
Control data for responses were obtained by taking fluorescence readings of each 
component separately when combined in the stopped-flow apparatus with buffer. 
To measure the dissociation rate of the DHFR-MTX complex, 2 μM enzyme was 
incubated with 10 μM methotrexate in MTEN buffer at pH 7. The enzyme-methotrexate 
solution was then mixed in a stopped-flow apparatus with 300 μM or 700 μM TMP to 
displace methotrexate. The dissociation event was monitored by following the 
fluorescence emission changes at 450 nm for 500s. 
To further explore the dissociation rate of the DHFR-MTX complex a 
concentration of 1 μM enzyme, 5 μM methotrexate, and 700 μM trimethoprim (TMP) in 
MTEN buffer at pH 7 was mixed (TMP mixed in immediately prior to fluorescence 
readings) and placed in a Flouromax SX20 spectrophotometer. The dissociation event 
was monitored by following the fluorescence emission changes at 450 nm for 600s and 
172800s (48h) 
 
Unlabeled apoenzyme Bs DHFR mixed with NADPH 
NADPH (2–200 µM) was mixed with 2 µM of C73A/S131C Bs DHFR in MTEN 
buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence emission 
intensity for C73A/S131C Bs DHFR (excitation at 290 nm, emission with a 320 nm 
cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25-
500s. Five individual traces were used to obtain an average trace for each condition. 
11 
 
Control data for responses were obtained by taking fluorescence readings of each 
component separately when combined in the stopped-flow apparatus with buffer. 
 
Labeled apoenzyme Bs DHFR mixed with NADPH 
NADPH (2– 200 µM) was mixed with 2 µM of C73A/S131CMDCC Bs DHFR in 
MTEN buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence 
emission intensity for C73A/S131CMDCC (excitation at 419 nm emission with a 450 nm 
cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25-
500s. Five individual traces were used to obtain an average trace for each condition. 
Control data for responses were obtained by taking fluorescence readings of each 
component separately when combined in the stopped-flow apparatus with buffer. 
 
Unlabeled holoenzyme Bs DHFR mixed with methotrexate 
Methotrexate (2– 200 µM) was mixed with 2 µM of C73A/S131C Bs DHFR, pre-
incubated with 10 µM NADPH, in MTEN buffer at pH 7 in the stopped-flow apparatus. 
The changes in fluorescence emission intensity for C73A/S131C Bs DHFR (excitation at 
290 nm, emission with a 320 nm cutoff filter) were recorded in the stopped-flow 
apparatus (slit widths 1 mm) for 0.25-500s. Five individual traces were used to obtain an 
average trace for each condition. Control data for responses were obtained by taking 
fluorescence readings of each component separately when combined in the stopped-flow 
apparatus with buffer. 
To measure the dissociation rate of the DHFR-NADPH-MTX complex, 2 μM 
enzyme incubated with 10 μM NADPH was incubated with 10 μM methotrexate in 
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MTEN buffer at pH 7. The enzyme-methotrexate solution was then mixed in a stopped-
flow apparatus with 300 μM or 700 μM TMP to displace methotrexate. The dissociation 
event was monitored by following the fluorescence emission changes at 320nm for 500s.  
To further explore the dissociation rate of the DHFR-NADPH-MTX complex a 
concentration of 1 μM enzyme, 5 μM NADPH, 5 μM methotrexate, and 700 μM 
trimethoprim (TMP) in MTEN buffer at pH 7 was mixed (TMP mixed in immediately 
prior to fluorescence readings) and placed in a Flouromax SX20 spectrophotometer. The 
dissociation event was monitored by following the fluorescence emission changes at 320 
nm for 600s and 172800s (48h) 
 
Labeled holoenzyme Bs DHFR mixed with methotrexate 
Methotrexate (2– 200 µM) was mixed with 2 µM of C73A/S131CMDCC Bs DHFR 
pre-incubated with 10 µM NADPH in MTEN buffer at pH 7 in the stopped-flow 
apparatus. The changes in fluorescence emission intensity C73A/S131CMDCC (excitation 
at 419 nm, emission with a 450 nm cutoff filter) were recorded in the stopped-flow 
apparatus (slit widths 1 mm) for 0.25-500s. Five individual traces were used to obtain an 
average trace for each condition. Control data for responses were obtained by taking 
fluorescence readings of each component separately when combined in the stopped-flow 
apparatus with buffer. 
To measure the dissociation rate of the DHFR-NADPH-MTX complex, 2 μM 
enzyme incubated with 10 μM NADPH was incubated with 10 μM methotrexate in 
MTEN buffer at pH 7. The enzyme-methotrexate solution was then mixed in a stopped-
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flow apparatus with 300 μM or 700 μM TMP to displace methotrexate. The dissociation 
event was monitored by following the fluorescence emission changes at 450 nm for 500s. 
To further explore the dissociation rate of the DHFR-NADPH-MTX complex a 
concentration of 1 μM enzyme, 5 μM NADPH, 5 μM methotrexate, and 700 μM 
trimethoprim (TMP) in MTEN buffer at pH 7 was mixed (TMP mixed in immediately 
prior to fluorescence readings) and placed in a Flouromax SX20 spectrophotometer. The 
dissociation event was monitored by following the fluorescence emission changes at 450 
nm for 600s and 172800s (48h) 
 
Data Analysis 
Data Analysis was done using Dynafit 4 [ 23 ], a minimization fitting program, to 
do an optimization analysis to fit the data to the following kinetic model. The model for 
the binding of methotrexate to Bs DHFR elucidated by previous studies (Fig. 4) was used 
as a basis for the Dynafit analysis. For each section of the model, only one, two steps, or 
pure conformational change step (E+LE.L, or E’+LE’.LE.L or E’.L 
E.L) were used with the goal of using as few steps as possible to adequately explain 
each set of the data. Each trace typically shows evidence of only one or two steps with all 
timescales and wavelength showing the whole picture. Dynafit files and scripts are found 
in each respective binding folder under the file heading: Dynafit Ready Data Files + 
Scripts. Binding (k1) steps were all successfully fit to a one step model and all 
conformational change (k2) steps were fit to a simple conformational change step as well 
as a two step model. 
14 
 
 
Figure 7: The minimal model for methotrexate binding to Bs DHFR. E and E’ represent 
different conformational states of Bs DHFR, L represents a ligand (Methotrexate or 
NADPH in this case), and E.L and E’.L represent different conformational states of Bs 
DHFR bound to a ligand. The rate constants are first order rate constants in units of s-1 for 
the conformational changes and second order rate constant μM- 1 s-1 for the ligand binding 
steps. 
Analysis for the data was carried out through an iterative process. Initial estimates 
for parameters such as enzyme, buffer, and ligand responses (Table 1) were determined 
from control data. Responses were determined by subtracting out the background 
fluorescence and dividing by concentration. The control parameters were constantly 
monitored to prevent significant deviation from measured values. These parameters 
included the response values for the enzyme alone, the response values for the ligand 
alone, and the offset which corresponds to the response generated by the buffer alone. 
Based on rough single exponential analysis of the emission vs. time curves, using 
multiple concentrations of methotrexate and NADPH mixed with the enzyme, initial 
parameter estimates for k1 along with the rough values for the known responses were 
used to get an initial calculation for the concentration of enzyme (Fig. 8). 
k
4
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-1
s
-1
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=0.02s
-1
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= 23μM
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EMTX 
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Figure 8: Initial estimates for binding constants. The estimate of the binding constant is 
indicated by the slope of a best fit linear line through the data (red box). Only the 
approximation of L MTX W.NADPH was quite far off in terms of precision. This data as 
well as the calculation of the kObs values for each concentration can be found in Folder: 
kObs graphs and data, within each of the corresponding binding folders. 
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This concentration reflects the percent of the enzyme that is in the E conformation 
for binding NADPH through the E+LEL pathway. This is important for knowing the 
distribution between E and E’ while the total enzyme concentration is known to be 1 μM. 
With nearly all parameters decently defined, each trace was run through an iterative 
process where the parameters were allowed to vary individually and in groups as well as 
all at once to develop a best fit trace for each fitting. The values from these were then 
used to determine global best fits across data sets. 
 
 
 NADPH  Binding 
  L U 
DHFR 1.92 0.477 
NADPH 0.000001 0.0352 
DHFR.NADPH 0.965 0.961 
DHFR'.NADPH 0.942 0.94 
  MTX  Binding   MTX   Binding 
  L U   L U 
DHFR 1.935 0.86 DHFR.NADPH 5.21 0.89 
MTX 0.00001 0.001 MTX 0.00001 0.001 
DHFR.MTX 0.934 0.756 DHFR.NADPH.MTX 5.1 0.856 
DHFR'.MTX 0.746 0.73 DHFR'.NADPH.MTX 5.1 0.83 
 
Table 1: Control values for the Dynafit response constants. Used as initial values and 
refined through the Dynafit iterative modeling process. File: Response Values. 
 
Results and Discussion 
Methotrexate Mixed with Bs DHFR 
Independently confirming the model of methotrexate binding and the rates at 
which methotrexate binds to Bs DHFR is important for further analysis. Knowing the 
rates of binding and conformational changes and how they are different for the 
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DHFR.NADPH system is important for determining NADPH’s role in methotrexate 
binding. Seeing the same previously observed conformational changes researched by 
Maryam Alapa would ideally confirm the conformational equilibrium in Bs DHFR [ 1 ]. 
The binding of methotrexate to unlabeled Bs DHFR causes a change in tryptophan 
fluorescence (290 nm) intensity. There are three tryptophan molecules (Trp22, Trp85 and 
Trp135) in our Bs DHFR enzyme, one of which is in the active site. These tryptophan 
molecules give off varying amounts of fluorescence depending on their local 
environment. For instance, one can clearly detect change in the fluorescence intensity 
when a molecule is binding to the active site and detect changes in fluorescence intensity 
as the protein shifts conformation [ 1 ] .  
The binding of methotrexate to unlabeled Bs DHFR causes a fast methotrexate 
concentration dependent decrease in tryptophan (290) fluorescence intensity.  There is 
also a second, slower decrease in fluorescence, the rate of which does not vary with 
methotrexate concentration. The traces were fitted to a two-step equation. The fast 
concentration dependent decrease is over within 0.25 seconds and has a k1 of 23.8 ±2.2 
μM- 1s-1 and k-1 was calculated to be 0.8 ±0.29 s-1. (Table 2) The fast step is attributed to 
methotrexate binding, k1, and the slower step is attributed to the conformational change, 
k2, as the DHFR-MTX complex moves to equilibrium between its two forms. The rate 
constant k2 was found to be 0.02 ±0.0027 s
-1. (Table 2) It was not possible to determine k-
2 from this particular data.  
The binding of methotrexate to labeled Bs DHFR causes a slower concentration 
dependent decrease in MDCC fluorescence (419 nm) intensity. The MDCC probe which 
is attached to the Bs DHFR at a distal site is sensitive to small changes in its local 
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environment changing fluorescence intensity as any binding or conformational changes 
occur. The traces were fitted to a two-step equation. This is a concentration dependent 
decrease is over within 100 seconds and has a k4 of 0.072 ±00013 μM- 1s-1 and a k-4 of 
approximately 0.0064 ±0.000066 s-1. (Table 2) 
Longer unlabeled traces showed a slow decrease in fluorescence intensity 
indicating a slow methotrexate concentration independent decrease. By running these 
samples at high methotrexate concentrations, the methotrexate concentration dependent 
step becomes so fast that it cannot be observed on the timescale of our data collection and 
all that can be seen is the concentration independent step. These longer traces were fit to 
a two-step model. The fast step is attributed to methotrexate binding (k1), and the slower 
step is attributed to the conformational change (k2) as the DHFR-MTX complex shifts its 
conformation finding a new conformation equilibrium with different amounts of DHFR 
being in each conformation. The rate constant k2 was fond to be 0.02 ±0.0027 s
-1 and k-2 
could not be calculated from the data. (Table 2)  
 
Figure 9: Model for the rates of binding and conformational changes associated 
with methotrexate binding to the unlabeled Bs DHFR and labeled Bs DHFR.  
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Figure 10: Unlabeled Bs DHFR (1 μM) mixed with various concentrations of MTX in 
MTEN buffer at pH 7 and at 25.7 °C (left). Data File: U MTX Binding No.NADPH 
0.25s Data. Data Folder: U MTX Binding No.NADPH. This shows a fast concentration 
dependent fluorescence decrease corresponding to the k1 step of rate 23.8 ±2.2 μM- 1s-1. 
Labeled Bs DHFR (1 μM) mixed with various concentrations of MTX in MTEN buffer at 
pH 7 and at 25.7 °C (right). Data File: L MTX Binding No.NADPH 100s Data. Data 
Folder: L MTX Binding No.NADPH. This shows a much slower concentration 
dependent fluorescence decrease corresponding to the k4 step of rate 0.072 ±00013 μM- 
1s-1. These analyses were done in Dynafit and the script files are located in the Dynafit 
Ready Data Files + Scripts folder within each relevant binding folder. These very 
different rates at two distinct timescales that are both concentration dependent is what 
indicates that there are two separate conformers binding at separate rates. This pattern 
was previously determined in prior research by Maryam Alapa [ 1 ]. Maryam Apala’s 
research yielded two k1 of 20.2 ±0.21 μM- 1s-1 and 23.99 ±1.9 μM- 1s-1 and a k4 of 0.067 
±0.0001 μM- 1s-1. These values are very close matches to my own. 
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Unlabeled 0.25s Average Standard Error 
k1 23.8 μM
- 1 s-1 2.2 
k-1 0.8 s
-1 0.29 
Unlabeled 100s   
k2 0.02 s
-1 0.0027 
k-2 N/A N/A 
Labeled 100s   
k4 0.072 μM
- 1 s-1 0.00013 
k-4 0.0064 s
-1 0.000066 
 
Table 2. Rates of binding and conformational changes associated with methotrexate 
binding to the unlabeled Bs DHFR and labeled Bs DHFR. Based on Dynafit calculation 
of and averaged 3-5 traces per concentration and 3-5 concentrations per rate. Data 
Folders: U MTX Binding No.NADPH, L MTX Binding No.NADPH. The script files are 
in the Dynafit Ready Data Files + Scripts folder within each relevant binding folder. 
 
Methotrexate binding to Bs DHFR can be modeled as two separate, two step 
processes. This implies that Bs DHFR is a dynamic system. Based on this and previous 
studies Bs DHFR like many enzymes is not rigid and at equilibrium is most often found 
in two forms (E and E’). The separate conformations of Bs DHFR bind methotrexate at 
different rates and the motions that Bs DHFR goes through after ligand binding 
(E+LE.L and E’+LE’L) can conform to a model where Bs DHFR undergoes a 
conformational change after binding takes place (EL  EL’). 
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Figure 11: Unlabeled Bs DHFR (1 μM) mixed with various concentrations of MTX in 
MTEN buffer at pH 7 and at 25.7 °C (left). Data File: U MTX Binding No.NADPH 100s 
Data. Data Folder: U MTX Binding No.NADPH. This shows a slow concentration 
independent fluorescence decrease that can be attributed to the k2 step of rate 0.02 
±0.0027 s-1 which is a conformational change. Unlabeled Bs DHFR (1 μM) mixed 2.5 
μM of MTX in MTEN buffer at pH 7 and at 25.7 °C, control sample was premixed for 5 
minutes (right). Data File: U MTX Binding No.NADPH 100s Data +control. Data 
Folder: U MTX Binding No.NADPH. The control run is mixed together and allowed to 
bind and settle into its conformations before reading its value providing a constant value 
with which the conformational change, which can often be subtle, can be more clearly 
visualized. The right graph zooms in and shows the conformational change.  
 
NADPH Mixed with Bs DHFR 
Determining how NADPH binds to Bs DHFR and what changes in conformation 
take place is important for clarifying our understanding of the NADPH/MTX/DHFR 
system. Seeing conformational changes in the DHFR.NADPH complex would suggest 
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that the conformational equilibrium in DHFR vs. the DHFR.NADPH system are different 
and should be treated differently. 
 The binding of NADPH to unlabeled Bs DHFR causes an NADPH concentration 
dependent increase in tryptophan fluorescence (290 nm) intensity. The traces were fitted 
to a single step model. This is a fast concentration dependent increase and is over within 
0.2 seconds and has a k1 of 19.5 ±0.18 μM- 1 s-1 and a k-1 of 3.9 ±0.11 s-1. (Table 3) 
 
  
Figure 12: Unlabeled Bs DHFR (1 μM) mixed with various concentrations of NADPH in 
MTEN buffer at pH 7 and at 25.2 °C (left). Data File: U NADPH Binding 0.25s Data. 
Data Folder: U NADPH Binding. This shows a fast concentration independent 
fluorescence increase that can be attributed to the k1 step of rate 19.5 ±0.18 μM- 1 s-1. 
Labeled Bs DHFR (1 μM) mixed with various concentrations of NADPH in MTEN 
buffer at pH 7 and at 25.2 °C (right). Data File: L NADPH Binding 0.25s Data. Data 
Folder: L NADPH Binding. This shows a fast concentration independent fluorescence 
decrease that can be attributed a k4 step of rate 35.6 ±0.11 μM- 1s-1. 
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The binding of NADPH to labeled Bs DHFR causes a NADPH concentration 
dependent decrease in MDCC fluorescence intensity. The traces were fitted to a single 
step equation. This is a fast concentration dependent decrease is over within 0.25 seconds 
and has a k4 of 35.6 ±0.15 μM- 1s-1 and a k-4 of near 0 s-1. (Table 3) 
Longer unlabeled traces showed a small decrease in fluorescence intensity 
indicating a slow NADPH concentration independent decrease. These longer traces were 
fit to a two-step model. The fast step is attributed to NADPH binding, k1, and the slower 
step is attributed to the conformational change, k2. The rate constant k2 was found to be 
0.02 ±0.0002 s-1 and k-2 could not be calculated from the data. 
Longer labeled traces showed a small decrease in fluorescence intensity indicating 
a slow NADPH independent decrease. These longer traces were fit to a single step model 
of a conformational change. The rate constant k-2 was fond to be 0.1 ±0.0041 s
-1 and k2 
was unable to be calculated from the data. (Table 3) 
NADPH binding to Bs DHFR, like methotrexate, can be modeled with two 
conformers binding ligand at different rates. It is likely that Bs DHFR existing as two 
conformers (E and E’) bind NADPH at different rates and the motions that Bs DHFR 
goes through after ligand binding (E+LE.L and E’+LE’L) can conform to a model 
where Bs DHFR undergoes a conformational change after binding takes place (EL  
EL’). 
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Figure 13: Unlabeled Bs DHFR (1 μM) mixed with various concentrations of NADPH in 
MTEN buffer at pH 7 and at 25.2 °C (left). Data File: U NADPH Binding 100s Data. 
Data Folder: U NADPH Binding. This shows a slow concentration independent 
fluorescence decrease that can be attributed to the k2 step of rate 0.02 ±0.0002 s
-1 which is 
a conformational change. Unlabeled Bs DHFR (1 μM) mixed with various concentrations 
of NADPH in MTEN buffer at pH 7 and at 25.2 °C (right). Data File: L NADPH 
Binding 100s Data. Data Folder: L NADPH Binding.  This shows a concentration 
independent fluorescence decrease that can be attributed to the k-2 step of rate 0.01 
±0.0041 s-1 which is a conformational change. 
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Figure 14: Model with the rates of binding and conformational changes associated with 
NADPH binding to the unlabeled Bs DHFR and labeled Bs DHFR. 
 
Unlabeled 0.25s Rate Standard Error 
k1 19.5μM
-1
s
-1
 0.18 
k-1 3.9s
-1
 0.11 
Unlabeled 100s   
k2 0.02 s
-1 0.0002 
Labeled 100s   
k-2 0.1 s
-1 0.0041 
Labeled 0.25s   
k4 35.6 μM
- 1s-1 0.15 
k-4 0 s
-1 0.023 
 
Table 3. Rates of binding and conformational changes associated with methotrexate 
binding to the unlabeled Bs DHFR and labeled Bs DHFR. Based on Dynafit calculation 
of and averaged 3-5 traces per concentration and 3-5 concentrations per rate. Data 
Folders: U NADPH Binding, and L NADPH Binding. The script files are in the Dynafit 
Ready Data Files + Scripts folder within each relevant binding folder. 
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Methotrexate mixed with DHFR/NADPH Holoenzyme 
Finally determining the differences in binding of ligands like methotrexate bind to 
the DHFR/NADPH holoenzyme complex can clarify the role of NADPH in Bs DHFR 
methotrexate binding and the importance of NADPH to the study and analysis of 
inhibitors. A significant change in binding, conformational equilibrium, and/or 
dissociation rate would be a clear indication of the importance NADPH being included in 
the analysis process. 
The binding of methotrexate to unlabeled holoenzyme causes a methotrexate 
concentration dependent decrease in tryptophan fluorescence intensity (Fig. 14 left). The 
traces were fitted to a single step model. This is a fast concentration dependent increase 
and is over within 0.25 seconds and has a k1 of 24.7 ±1.1 μM- 1 s-1 and a k-1 of 0.03 ±0.4 s-
1. (Table 4) 
The binding of methotrexate to labeled holoenzyme causes a methotrexate 
concentration dependent decrease in MDCC fluorescence intensity (Fig. 14 right). The 
traces were fitted to a single step equation. This is a much slower concentration 
dependent decrease and is over within 100 seconds and has a k4 of 0.052 ±0.024 μM- 1s-1 
and a k-4 of 0.03 ±0.01 s
-1. (Table 4) 
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Figure 15: Unlabeled Bs DHFR (1 μM) premixed with NADPH (5 μM) and then mixed 
with various concentrations of MTX in MTEN buffer at pH 7 and at 25.7 °C (left). Data 
File: U MTX Binding W.NADPH 0.25s Data. Data Folder: U MTX Binding 
W.NADPH. This shows a fast concentration dependent fluorescence decrease 
corresponding to the k1 step of rate 24.7 ±1.1 μM- 1 s-1. Labeled Bs DHFR (1 μM) 
premixed with NADPH (5 μM) and then mixed with various concentrations of MTX in 
MTEN buffer at pH 7 and at 25.7 °C (right). Data File: L MTX Binding W.NADPH 
100s Data. Data Folder: L MTX Binding W.NADPH This shows a much slower 
concentration dependent fluorescence decrease corresponding to the k4 step of rate 0.052 
±0.024 μM- 1s-1. 
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Figure 16: Model for the rates of binding and conformational changes associated with 
methotrexate binding to the unlabeled DHFR.NADPH complex and labeled 
DHFR.NADPH complex. 
 
Unlabeled 0.25s Average Standard Error 
k1 24.7 μM
- 1s-1 1.1 
k-1 0.03 s
-1 0.4 
Unlabeled 100s   
k2 0.054 s
-1 0.0019 
k-2 N/A N/A 
Labeled 100s   
k4 0.052 μM
- 1s-1 0.024 
k-4 0.03 s
-1 0.01 
 
Table 4. Rates of binding and conformational changes associated with methotrexate 
binding to the unlabeled DHFR.NADPH complex and labeled Bs DHFR.NADPH 
complex. Based on Dynafit calculation of and averaged 3-5 traces per concentration and 
3-5 concentrations per rate. Data Folders: U MTX Binding W.NADPH, L MTX Binding 
W.NADPH. The script files are in the Dynafit Ready Data Files + Scripts folder within 
each relevant binding folder. 
 
k
4
= 0.052μM
-1
s
-1
 
k
-4 
=0.03s
-1
 
ENADPH’ + MTX ENADPH’MTX 
k
1
= 24.7μM
-1
s
-1
 
k
-1
= 0.03s
-1
 
ENADPH + MTX 
ENADPHMTX 
k
-2=N/A
 k2=0.054 s
-1
 k
-3
 k3 
29 
 
 
Dissociation rates of methotrexate from Bs DHFR and the DHFR.NADPH complex 
Determining the differences in the dissociation of ligands like methotrexate from 
Bs DHFR and the DHFR.NADPH complex can clarify the role of NADPH in Bs DHFR 
methotrexate binding and the importance of NADPH to the study and analysis of 
inhibitors. A significant change in dissociation, indicates an importance of the cofactor in 
not just activating the enzyme but preventing ligands from dissociating. 
The dissociation of methotrexate from unlabeled Bs DHFR causes a decrease in 
tryptophan fluorescence intensity (Fig. 16 left). The rates were calculated an exponential 
decay model. This shows a fluorescence decrease corresponding to the dissociation rate 
of 0.015 s-1 ±0.007965. 
The dissociation of methotrexate from labeled Bs DHFR causes an increase in 
tryptophan fluorescence intensity (Fig. 16 right). The rates were calculated an 
exponential rise model. This shows a fluorescence increase corresponding to the 
dissociation rate of 0.02 s-1 ±0.0000921. 
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Figure 17: Unlabeled Bs DHFR (1 μM) premixed with methotrexate (5 μM) mixed with 
trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and at 25.2 °C (left). Data File: U 
MTX Dissociation No NADPH Data. Data Folder: U MTX Dissociation No.NADPH. 
This shows a fluorescence decrease corresponding to the dissociation rate of 0.015 s-1 
±0.007965. Labeled Bs DHFR (1 μM) premixed with methotrexate (5 μM) and then 
mixed with trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and at 25.2 °C (right). 
Data File: L MTX Dissociation No NADPH Data. Data Folder: L MTX Dissociation 
No.NADPH. This shows a fluorescence increase corresponding to the dissociation rate of 
0.02 s-1 ±0.0000921. 
 
The dissociation of methotrexate from the unlabeled DHFR.NADPH complex 
causes a decrease in tryptophan fluorescence intensity (Fig. 17 left). The rates were 
calculated an exponential decay model. This shows a fluorescence decrease 
corresponding to the dissociation rate of 2.87e-5 s-1 ±0.82 e-5. 
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Figure 18: Unlabeled Bs DHFR (1 μM) premixed with methotrexate (5 μM) mixed with 
trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and at 25.2 °C (left). Data File: U 
MTX Dissociation With NADPH Data. Data Folder: U MTX Dissociation W.NADPH. 
This shows a fluorescence decrease corresponding to the dissociation rate of 2.87e-5 s-1 
±0.82 e-5. Labeled Bs DHFR (1 μM) premixed with methotrexate (5 μM), and NADPH 
(5 μM), and then mixed with trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and 
at 25.2 °C (right). Data File: Labeled MTX Dissociation With NADPH Data. Data 
Folder: L MTX Dissociation W.NADPH. This shows a fluorescence increase 
corresponding to the dissociation rate of 2.1e-5 s-1 ±0.271 e-5. This specific dissociation 
curve for the labeled enzyme had irregularities that appeared in the control experiment. 
(run 48 hours without NADPH) The control was used in file L MTX Dissociation 
W.NADPH and was subtracted from the average dissociation curve to correct for the 
irregularities. 
 The dissociation of methotrexate from the labeled DHFR.NADPH complex 
causes an increase in tryptophan fluorescence intensity (Fig. 17 right). The rates were 
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calculated an exponential rise model. This shows a fluorescence increase corresponding 
to the dissociation rate of 2.1e-5 s-1 ±0.271 e-5. 
Discussion 
Previously determined experimental results were verified by our experiments and 
the kinetic data is consistent with previously determined models for methotrexate 
binding. We confirmed that Bs DHFR exists in two distinct configurations E and E’ at a 
ratio of 0.7:0.3. We have extended scope of the model to include the cofactor NADPH 
binding resulting in a ENADPH and E’NADPH ratio of 0.6:0.4. This multistep model is 
supported by the distinct NADPH and methotrexate binding rates calculated from 
tryptophan fluorescence and the MDCC fluorophore fluorescence. Furthermore, the 
model is valid when methotrexate binding to the holoenzyme is determined following 
NADPH bindings. 
The difference in rate of methotrexate binding between the apoenzyme and the 
holoenzyme is indicative of the importance of the cofactor. However, the most significant 
change from the binding of Bs DHFR to NADPH is that the dissociation rate of 
methotrexate from the bound complex is reduced. This shift results in an increase in 
stability. This makes sense from a biological perspective as it ensures that when all 
components are present in solution that they not only bind to each other at an appropriate 
speed but also that they remain bound so that they achieve an appropriate reaction rate. 
The scale of the shift in dissociation rate is very interesting. The dissociation rate of the 
Bs DHFR without cofactor is fast while with cofactor it is 1000 times slower, a drastic 
decrease (Fig. 18).  
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Figure 19: Labeled methotrexate dissociation without NADPH (Fig. 16 right) compared 
to with NADPH (Fig. 17 right). Here we can clearly visualize the difference in timescale 
caused by NADPH. When there is no NADPH the timescale for dissociation is 600 
seconds with a rate of 0.02 s-1 ±0.0000921 and when there is NADPH the timescale for 
dissociation is 48 hours with a rate of 2.1e-5 s-1 ±0.271 e-5. 
 
We can conclude that important information regarding the kinetics of enzymes 
and of Bs DHFR in particular are missing if the analysis of inhibitor binding data is 
preformed while a key cofactor is missing. This is especially true when analyzing 
pharmaceuticals. For example, a cell with high energy (high NADPH concentration) 
would remain inhibited by methotrexate for much longer than a cell with low energy. 
This difference could alter effectiveness and toxicity so should be carefully analyzed. 
 
  
0
0.7
1.4
2.1
2.8
3.5
0 150 300 450 600
Labeled MTX Dissosiation No NADPH
F
lu
o
re
c
e
n
c
e
 I
n
te
n
s
it
y
(x
1
0
6
) 
(4
1
9
 n
m
)
Time (s)
0
0.7
1.4
2.1
2.8
3.5
0 12 24 36 48
Labeled MTX Dissosiation With NADPH
F
lu
o
re
c
e
n
c
e
 I
n
te
n
s
it
y
(x
1
0
6
) 
(4
1
9
 n
m
)
Time (h)
34 
 
References 
1. Alapa, M. T. (2012). Conformational motions associated with ligand binding in 
dihydrofolate reductase from bacillus stearothermophilus, (master’s thesis). 
Montclair State University, Montclair, NJ 
2. Appleman J.R., Howell E.E., Kraut J., Blakley R.L. (1990) Role of aspartate 27 of 
dihydrofolate reductase from Escherichia coli in interconversion of active and 
inactive enzyme conformers and binding of NADPH. Journal of Biological 
Chemistry. 265 55795584. 
3. Benkovic, S.J., Hammes-Schiffer, S. (2003) A perspective on enzyme catalysis. 
Science. 1196-1202. 
4. Boehr D.D., McElheny D., Dyson H.J., Wright P.E. (2006) The dynamic energy 
landscape of dihydrofolate reductase catalysis. Science. 313 1095-9203. 
5. Boehr D.D., Nussinov R., Wright P.E. (2009) The role of dynamic conformational 
ensembles in biomolecular recognition. Nat Chem Biol. 5 789-796 
6. Csermely P., Palotai R., Nussinov R., (2010). Induced fit, conformational 
selection and independent dynamic segments: an extended view of binding 
events. Nature Proceedings.   
7. Eyring H., Polanyi M. (1935) Some applications of the transition state method to 
calculation of reaction velocities, especially in solution. Trans. Faraday Soc. 31 
875-894. 
8. Falzone C.J., Wright P.E., Benkovic S.J. (1993) Dynamics of a Flexible Loop in 
Dihydrofolate Reductase from Escherichia coli and Its Implication for Catalysis. 
Biochemistry. 33 439-442. 
9. Falzone C.J., Wright P.E., Benkovic S.J., (1991) Evidence for Two 
Interconverting Protein Isomers in the Methotrexate Complex of Dihydrofolate 
Reductase from Escherichia coli. Biochemistry. 30 2184-2191.  
10. Goodey N.M., Alapa M.T., Hagmann D.F., Korunow S.G., Mauro A.K., Kwon 
K.S., Hall S.M. (2011) Development of a fluorescently labeled thermostable 
DHFR for studying conformational changes associated with inhibitor binding. 
Biochem Biophys Res Commun. 413 442-447 
11. Goodey N.M., Benkovic S.J. (2008) Allosteric regulation and catalysis emerge 
via a common route. Nature Chemical Biology. 4 474-482. 
12. Goodey N.M., Herbert K.G., Hall S.M., Bagley K.C. (2011) Prediction of 
residues involved in inhibitor specificity in the dihydrofolate reductase family. 
Biochem Biophys Acta. 1814 1870-1879. 
13. Hammes G., Chang Y.-C., Oas T., (2009) Conformational selection or induced fit: 
A flux description of reaction mechanism. Proceedings of National Academy of 
Sciences of the United States of America. 106 13737-13741.  
14. Hammes, G.G., Benkovic, S.J., Hammes-Schiffer, S. (2011) Flexibility, diversity, 
and cooperativity: pillars of enzyme catalysis. Biochemistry. 50 10422-10430 
35 
 
15. Hammes-Schiffer S., Watney J.B. (2006) Hydride transfer catalyzed by 
Escherichia coli and Bacillus subtilis dihydrofolate reductase: coupled motions 
and distal mutations. Philos Trans R Soc Lond B Biol Sci. 361 1365-1373. 
16. Hatzakis N.S. (2014) Single molecule insights on conformational selection and 
induced fit mechanism. Biophys Chem. 186 46-54. 
17. Hecht D., Tran J., Fogel G.B. (2011) Structural-based analysis of dihydrofolate 
reductase evolution. Mol Phylogenet Evol. 61 212-230. 
18. Horiuchi Y., Ohmae E., Tate S., Gekko K. (2010) Coupling effects of distal loops 
on structural stability and enzymatic activity of Escherichia coli dihydrofolate 
reductase revealed by deletion mutants. Biochem Biophys Acta. 1804(4):846-55 
19. Huennekens F.M., (1994) The methotrexate story: A paradigm for development 
of cancer chemotherapeutic agents. Advances in Enzyme Regulation. 34397-419. 
20. Johnson K., (2008) Role of Induced Fit in Enzyme Specificity: A Molecular 
Forward/Reverse Switch. Journal of Biological Chemistry. 283 26297-26301.  
21. Kim H.S., Damo S.M., Lee S.Y., Wemmer D., Klinman, J.P. (2005) Structure and 
hydride transfer mechanism of a moderate thermophilic dihydrofolate reductase 
from Bacillus stearothermophilus and comparison to its mesophilic and hyper 
thermophilic homologues. Biochemistry. 44 11428-11439. 
22. Kompis I., Islam K., Then R., (2005) DNA and RNA synthesis: antifolates. 
Chemical Reviews. 105 593-620. 
23. Kuzmic P., (1996) Program DYNAFIT for the Analysis of Enzyme Kinetic Data: 
Application to HIV Proteinase, Analytical Biochemistry 237 260-273. 
24. Li L., Falzone C.J., Wright P.E., Benkovic S.J. (1992) Functional Role of a 
Mobile Loop of Escherichia coli Dihydrofolate Reductase in Transition-State 
Stabilization. Biochemistry. 31 7826-7833.22   
25. Limited, A.P. (2006) SX20 Hardware User Guide. 
26. Liu, T., Whitten S.T., Hilser V.J. (2006) Ensemble-Based Signatures of Energy 
Propagation in Proteins: A New View of an Old Phenomenon. PROTEINS: 
Structure, Function, and Bioinformatics. 62:728–738  
27. Mauldin R.V., Carroll M.J., Lee A.L., (2009) Dynamic Dysfunction in 
Dihydrofolate Reductase Results from Antifolate Drug Binding: Modulation of 
Dynamics within a Structural State. Structure. 17 386-394.  
28. Morrison, J.F. (1969) Kinetics of the reversible inhibition of enzyme-catalyzed 
reactions by tight binding inhibitors. BIochimica et Biophysica Acta. 185 269-
286. 
29. Nussinov R., Ma B., Tsai, C.J. (2014) Multiple conformational selection and 
induced fit events take place in allosteric propagation. Biophys Chem. 186 22-30. 
30. Okondo, Marian. (2015). Effects of allosteric mutations on dihydrofolate 
reductase, (master’s thesis). Montclair State University, Montclair, NJ 
31. Oyeyemi O., Sours K.M., Lee T., Resing K.A., Ahn N.G., Klinman J.P. (2010) 
Temperature dependence of protein motions in a thermophilic dihydrofolate 
reductase and its relationship to catalytic efficiency. Proceedings of National 
Academy of Sciences of the United States of America. 107 10074-10079.  
36 
 
32. Pan H., Lee J.C., Hilser V.J. (2000) Binding sites in Escherichia coli 
dihydrofolate reductase communicate by modulating the conformational 
ensemble. Proceedings of National Academy of Sciences of the United States of 
America. 97 12020-12025.  
33. Patel S., Little M., Goodey N.M. (2014) Allosteric Ligand Specificity 
Determining Regions in the Dihydrofolate Reductase Family. 
34. QIAGEN. (2012) QIAprep® Miniprep Handbook, 2 ed. 
35. Rajagopalan R.T., Zhang Z., McCourt L., Dwyer M., Benkovic S.J., Hammes 
G.G., (2002) Interaction of dihydrofolate reductase with methotrexate: Ensemble 
and single molecule kinetics. Proceedings of National Academy of Sciences of the 
United States of America. 99 13481-13486. 
36. Rod T.H., Radkiewicz J.L., Brooks C.L. (2003) Correlated motion and the effect 
of distal mutations in dihydrofolate reductase. Proc Natl Acad Sci. 100 6980-
6985. 
37. Sasso S.P., Gilli R.M., Sari J.C., Rimet O.S., Briand C.M. (1994) Thermodynamic 
study of dihydrofolate reductase inhibitor selectivity. Biochemica et Biophysica 
Acta. 1207 74-79.  
38. Sawaya M., Kraut J. (1997) Loop and Subdomain Movements in the Mechanism 
of Escherichia coli Dihydrofolate Reductase: Crystallographic Evidence. 
Biochemistry. 36 586603. 
39. Schiffer S.H., Benkovic S.J. (2006) Relating Protein Motion to Catalysis. Annual 
Review of Biochemistry. 75 519-541. 
40. Schnell J.R., Dyson H.J., Wright P.E., (2004) Structure, dynamics, and catalytic 
function of dihydrofolate reductase. Annual Review of Biochemistry. 33 119-140. 
41. Schweitzer, B.I., Dicker, A.P., Bertino, J.R. (1990) Dihydrofolate reductase as a 
therapeutic target. The FASEB Journal. 4 2441-2452. 
42. Sharma M., Chauhan P.M. (2012) Dihydrofolate reductase as a therapeutic target 
for infectious diseases: opportunities and challenges. Future Medicinal Chemistry. 
4 1335-1365. 
43. Silva D.A., Bowman G., Sosa-Peinado A., Huang X., (2011) A Role for Both 
Conformational Selection and Induced Fit in Ligand Binding by the LAO Protein. 
Public Library of Science Computational Biology. 7 e1002054  
44. Singh P., Sen A., Francis K., Kohen A. (2014) Extension and limits of the 
network of coupled motions correlated to hydride transfer in dihydrofolate 
reductase. J Am Chem Soc. 136 2575-2582. 
45. Stone S.R., Morrison J.F. (1982) Kinetic mechanism of the reaction catalyzed by 
dihydrofolate reductase from Escherichia coli. Biochemistry. 21 3757-3765.  
46. Teague S.J., (2003) Implications of Protein Flexibility for Drug Discovery. Nature 
Reviews. 2 527-541. 
47. Verma C.S., Caves L.S., Hubbard R.E., Roberts G.C. (1997) Domain motions in 
dihydrofolate reductase: a molecular dynamics study. J Mol Biol. 266 776-796. 
48. Vogt A.D., Pozzi N., Chen Z., Di Cera E. (2014) Essential role of conformational 
selection in ligand binding. Biophys Chem. 186 13-21. 
37 
 
Appendix 
 
𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆
𝑬𝒙𝒕𝒊𝒏𝒄𝒕𝒊𝒐𝒏 𝒄𝒐𝒆𝒇𝒇𝒊𝒄𝒆𝒏𝒕 (𝑴−𝟏𝒄𝒎−𝟏) ∗  𝑷𝒂𝒕𝒉 𝒍𝒆𝒏𝒈𝒕𝒉 (𝒄𝒎)
= 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏(𝑴) 
 
𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟒𝟏𝟗 𝒏𝒎)
𝑬𝒙𝒕. 𝒄𝒐𝒆𝒇𝒇, (𝟓𝟎𝟎𝟎𝟎𝑴−𝟏𝒄𝒎−𝟏) ∗  𝑷𝒂𝒕𝒉 𝒍𝒆𝒏𝒈𝒕𝒉 (𝟎. 𝟏𝒄𝒎)
= 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴) 
 
𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴) ∗  𝑬𝒙𝒕. 𝒄𝒐𝒆𝒇𝒇, (𝟏𝟎𝟎𝟎𝟎𝑴−𝟏𝒄𝒎−𝟏)
∗  𝑷𝒂𝒕𝒉 𝒍𝒆𝒏𝒈𝒕𝒉 (𝟎. 𝟏𝒄𝒎) =  𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟐𝟖𝟎 𝒏𝒎) 
 
𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑻𝒐𝒕𝒂𝒍 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟐𝟖𝟎 𝒏𝒎) − 𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟐𝟖𝟎 𝒏𝒎)
=  𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑼 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟐𝟖𝟎 𝒏𝒎)  
 
𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑼 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟐𝟖𝟎 𝒏𝒎)
𝑬𝒙𝒕. 𝒄𝒐𝒆𝒇𝒇, (𝟐𝟓𝟓𝟔𝟓𝑴−𝟏𝒄𝒎−𝟏) ∗  𝑷𝒂𝒕𝒉 𝒍𝒆𝒏𝒈𝒕𝒉 (𝟎. 𝟏𝒄𝒎)
= 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑼 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴) 
 
𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴)
𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑼 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴) +  𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴)
= 𝑳𝒂𝒃𝒆𝒍𝒊𝒏𝒈 𝑬𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚 
 
Figure 20: Equation for converting absorbance to concentration and for measuring 
labeling efficiency. Absorbance of labeled enzyme at 419 nm and of total enzyme at 280 
nm are the measured values for calculating labeling efficiency. 
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A280 = ext. coeff C (M) l cm   
0.14  25565 5.47624E-05 0.1   
   54.76237043 uM   
  0.00125 L 0.068452963 umol  
Label       
mg/ml mg/mmol umol/ul ul  0.068452963 umol enzyme 
0.22 383.4 0.000573813 357.8845367  0.205358889 umol label 
       
labeling       
A419 L = ext. coeff C  (M) l cm   
0.189  50000 0.0000378 0.1   
   37.8 uM   
A280 E =0.135 - A280 L     
0.0972  25565 3.80207E-05 0.1   
   38.02073147 uM   
A280 L       
0.0378  10000 0.0000378 0.1   
   37.8 uM   
    0.994194444 labeling  efficiency 
 
Figure 21: Sample calculation sheet of absorbance, needed label concentration, and 
labeling efficiency using the equations laid out in Fig. 19 File: Absorbance Calculation 
(In the base data folder). Bold values are measured values and the file auto calculates 
everything else. 
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Inventory 
Box 1 DHFR supplies 
A. 2x 0.5mL tube MTX 35.4mM 
B. 1x 1.5mL tube MTX 1000uM 
C. 1x 1.5mL tube NADPH 1000uM 
D. 1x 0.5mL tube TMP 365mM 
E. 1x 1.5mL tubes of labeled enzyme 
F. 4x 0.5mL tubes of Labeled enzyme 47.29uM 
G. 1x 1.5mL tube of transformed E. coli cell culture C73A, S131C 
H. 3x1.5mL tubes of unlabeled enzyme 
I. 1x 1.5mL tube MDCC old Stock 
J. 2x 0.5mL tube of MDCC at 0.22mg/mL 
K. 4x 0.5mL tube of unknown (variable) concentration of MDCC (contain 
particulate) 
(box #2 was combined into box 1) 
 
 
 
 
 
 
A 
B 
C 
D 
E 
F 
G 
H 
I J 
K 
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Box #3 DHFR pellets 
A. 2x Falcon tubes each contain a cell pellet 
B. 1x 10 mL tube with DHFR 
 
Box 4 Maryam Legacy box 
A. Old Pellets from 2012 
B. 1x 1.5mL tube of transformed E. coli cell culture C73A, S131C 
 
A 
B 
A B 
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Box 1, 3, 4 in the stand     The stand (A) in the Freezer
 
1 
2 3 
A 
